nodes	percent_of_prediction	percent_of_DWPC	metapath
Methylphenidate—CYP2D6—Gefitinib—lung cancer	0.0646	0.32	CbGbCtD
Methylphenidate—CYP2D6—Vinorelbine—lung cancer	0.0497	0.246	CbGbCtD
Methylphenidate—CYP2D6—Erlotinib—lung cancer	0.0382	0.189	CbGbCtD
Methylphenidate—CYP2D6—Vinblastine—lung cancer	0.0307	0.152	CbGbCtD
Methylphenidate—CYP2D6—Doxorubicin—lung cancer	0.0188	0.0933	CbGbCtD
Methylphenidate—SLC6A3—Parkinsons Disease Pathway—UCHL1—lung cancer	0.00236	0.0219	CbGpPWpGaD
Methylphenidate—CYP2D6—Fatty acids—CYP2A7—lung cancer	0.00216	0.02	CbGpPWpGaD
Methylphenidate—SLC6A3—Alpha-synuclein signaling—FGR—lung cancer	0.00187	0.0174	CbGpPWpGaD
Methylphenidate—SLC6A3—Dopaminergic Neurogenesis—SOX2—lung cancer	0.00179	0.0166	CbGpPWpGaD
Methylphenidate—CYP2D6—Xenobiotics—CYP2A7—lung cancer	0.00171	0.0159	CbGpPWpGaD
Methylphenidate—CYP2D6—CYP2E1 reactions—CYP2A6—lung cancer	0.00161	0.0149	CbGpPWpGaD
Methylphenidate—SLC6A2—Transport of glucose and other sugars, bile salts and organic acids, metal ions and amine compounds—SLC22A18—lung cancer	0.00148	0.0137	CbGpPWpGaD
Methylphenidate—CYP2D6—Codeine and Morphine Metabolism—ABCB1—lung cancer	0.00138	0.0128	CbGpPWpGaD
Methylphenidate—CYP2D6—CYP2E1 reactions—CYP2E1—lung cancer	0.00137	0.0127	CbGpPWpGaD
Methylphenidate—SLC6A3—Transport of glucose and other sugars, bile salts and organic acids, metal ions and amine compounds—SLC22A18—lung cancer	0.00131	0.0121	CbGpPWpGaD
Methylphenidate—CYP2D6—Fatty Acid Omega Oxidation—CYP2A6—lung cancer	0.00119	0.011	CbGpPWpGaD
Methylphenidate—SLC6A4—NRF2 pathway—PRDX1—lung cancer	0.00115	0.0107	CbGpPWpGaD
Methylphenidate—SLC6A4—NRF2 pathway—GSTM2—lung cancer	0.00108	0.01	CbGpPWpGaD
Methylphenidate—CYP2D6—Fatty Acid Omega Oxidation—CYP2E1—lung cancer	0.00101	0.00939	CbGpPWpGaD
Methylphenidate—CYP2D6—Xenobiotics—CYP2A6—lung cancer	0.000996	0.00924	CbGpPWpGaD
Methylphenidate—SLC6A2—NRF2 pathway—PRDX1—lung cancer	0.000991	0.00919	CbGpPWpGaD
Methylphenidate—CYP2D6—Tamoxifen metabolism—CYP2A6—lung cancer	0.000958	0.00888	CbGpPWpGaD
Methylphenidate—SLC6A2—NRF2 pathway—GSTM2—lung cancer	0.000931	0.00864	CbGpPWpGaD
Methylphenidate—SLC6A4—Circadian rythm related genes—KMT2A—lung cancer	0.000892	0.00827	CbGpPWpGaD
Methylphenidate—SLC6A4—SIDS Susceptibility Pathways—CHRNB4—lung cancer	0.000891	0.00826	CbGpPWpGaD
Methylphenidate—SLC6A2—SLC-mediated transmembrane transport—SLC34A2—lung cancer	0.000886	0.00822	CbGpPWpGaD
Methylphenidate—SLC6A3—NRF2 pathway—PRDX1—lung cancer	0.000878	0.00814	CbGpPWpGaD
Methylphenidate—SLC6A4—NRF2 pathway—GSTA3—lung cancer	0.000873	0.0081	CbGpPWpGaD
Methylphenidate—CYP2D6—Xenobiotics—CYP2E1—lung cancer	0.000847	0.00785	CbGpPWpGaD
Methylphenidate—SLC6A3—NRF2 pathway—GSTM2—lung cancer	0.000825	0.00765	CbGpPWpGaD
Methylphenidate—SLC6A4—NRF2 pathway—KEAP1—lung cancer	0.000821	0.00761	CbGpPWpGaD
Methylphenidate—SLC6A4—Circadian rythm related genes—TOP1—lung cancer	0.000816	0.00757	CbGpPWpGaD
Methylphenidate—CYP2D6—Tamoxifen metabolism—CYP2E1—lung cancer	0.000814	0.00755	CbGpPWpGaD
Methylphenidate—SLC6A4—NRF2 pathway—GSTA4—lung cancer	0.000799	0.00741	CbGpPWpGaD
Methylphenidate—SLC6A4—Circadian rythm related genes—NKX2-1—lung cancer	0.000795	0.00737	CbGpPWpGaD
Methylphenidate—SLC6A3—SLC-mediated transmembrane transport—SLC34A2—lung cancer	0.000785	0.00728	CbGpPWpGaD
Methylphenidate—SLC6A4—NRF2 pathway—GSTA2—lung cancer	0.000778	0.00722	CbGpPWpGaD
Methylphenidate—SLC6A4—NRF2 pathway—GSTA1—lung cancer	0.000751	0.00696	CbGpPWpGaD
Methylphenidate—SLC6A2—NRF2 pathway—GSTA3—lung cancer	0.000751	0.00696	CbGpPWpGaD
Methylphenidate—SLC6A4—NRF2 pathway—ABCC3—lung cancer	0.000742	0.00688	CbGpPWpGaD
Methylphenidate—CYP2D6—Fatty Acid Omega Oxidation—CYP1A1—lung cancer	0.000727	0.00674	CbGpPWpGaD
Methylphenidate—CYP2D6—Cytochrome P450 - arranged by substrate type—CYP2A7—lung cancer	0.000712	0.0066	CbGpPWpGaD
Methylphenidate—SLC6A2—NRF2 pathway—KEAP1—lung cancer	0.000706	0.00655	CbGpPWpGaD
Methylphenidate—CYP2D6—Oxidation by Cytochrome P450—CYP2A7—lung cancer	0.000703	0.00652	CbGpPWpGaD
Methylphenidate—SLC6A4—NRF2 pathway—UGT1A1—lung cancer	0.000698	0.00647	CbGpPWpGaD
Methylphenidate—SLC6A2—NRF2 pathway—GSTA4—lung cancer	0.000687	0.00637	CbGpPWpGaD
Methylphenidate—SLC6A3—Transmission across Chemical Synapses—GRIK3—lung cancer	0.000682	0.00633	CbGpPWpGaD
Methylphenidate—SLC6A4—SIDS Susceptibility Pathways—FOXM1—lung cancer	0.000675	0.00626	CbGpPWpGaD
Methylphenidate—SLC6A2—SLC-mediated transmembrane transport—SLC22A18—lung cancer	0.000672	0.00623	CbGpPWpGaD
Methylphenidate—SLC6A2—NRF2 pathway—GSTA2—lung cancer	0.000669	0.00621	CbGpPWpGaD
Methylphenidate—SLC6A3—NRF2 pathway—GSTA3—lung cancer	0.000665	0.00617	CbGpPWpGaD
Methylphenidate—SLC6A4—NRF2 pathway—NFE2L2—lung cancer	0.000662	0.00614	CbGpPWpGaD
Methylphenidate—SLC6A2—NRF2 pathway—GSTA1—lung cancer	0.000646	0.00599	CbGpPWpGaD
Methylphenidate—SLC6A2—NRF2 pathway—ABCC3—lung cancer	0.000638	0.00592	CbGpPWpGaD
Methylphenidate—SLC6A4—NRF2 pathway—TGFA—lung cancer	0.000631	0.00585	CbGpPWpGaD
Methylphenidate—SLC6A4—SIDS Susceptibility Pathways—SOX2—lung cancer	0.000628	0.00582	CbGpPWpGaD
Methylphenidate—SLC6A3—NRF2 pathway—KEAP1—lung cancer	0.000625	0.0058	CbGpPWpGaD
Methylphenidate—CYP2D6—Xenobiotics—CYP1A1—lung cancer	0.000608	0.00564	CbGpPWpGaD
Methylphenidate—SLC6A3—NRF2 pathway—GSTA4—lung cancer	0.000608	0.00564	CbGpPWpGaD
Methylphenidate—SLC6A4—SIDS Susceptibility Pathways—ALDOA—lung cancer	0.000608	0.00564	CbGpPWpGaD
Methylphenidate—SLC6A2—NRF2 pathway—UGT1A1—lung cancer	0.0006	0.00557	CbGpPWpGaD
Methylphenidate—SLC6A3—SLC-mediated transmembrane transport—SLC22A18—lung cancer	0.000595	0.00552	CbGpPWpGaD
Methylphenidate—SLC6A3—NRF2 pathway—GSTA2—lung cancer	0.000593	0.0055	CbGpPWpGaD
Methylphenidate—CYP2D6—Tamoxifen metabolism—CYP1A1—lung cancer	0.000585	0.00543	CbGpPWpGaD
Methylphenidate—CYP2D6—Phase 1 - Functionalization of compounds—CYP2A7—lung cancer	0.000577	0.00535	CbGpPWpGaD
Methylphenidate—SLC6A3—NRF2 pathway—GSTA1—lung cancer	0.000572	0.0053	CbGpPWpGaD
Methylphenidate—SLC6A2—NRF2 pathway—NFE2L2—lung cancer	0.000569	0.00528	CbGpPWpGaD
Methylphenidate—SLC6A4—NRF2 pathway—GCLC—lung cancer	0.000569	0.00528	CbGpPWpGaD
Methylphenidate—SLC6A4—NRF2 pathway—CYP2A6—lung cancer	0.000569	0.00528	CbGpPWpGaD
Methylphenidate—SLC6A3—NRF2 pathway—ABCC3—lung cancer	0.000566	0.00524	CbGpPWpGaD
Methylphenidate—SLC6A3—Transmission across Chemical Synapses—CHRNB4—lung cancer	0.000556	0.00516	CbGpPWpGaD
Methylphenidate—SLC6A2—NRF2 pathway—TGFA—lung cancer	0.000543	0.00503	CbGpPWpGaD
Methylphenidate—SLC6A4—SIDS Susceptibility Pathways—TF—lung cancer	0.000534	0.00495	CbGpPWpGaD
Methylphenidate—SLC6A3—NRF2 pathway—UGT1A1—lung cancer	0.000532	0.00493	CbGpPWpGaD
Methylphenidate—SLC6A4—Circadian rythm related genes—AHR—lung cancer	0.000526	0.00488	CbGpPWpGaD
Methylphenidate—SLC6A3—Neuronal System—GRIK3—lung cancer	0.000523	0.00485	CbGpPWpGaD
Methylphenidate—SLC6A3—Transmission across Chemical Synapses—CHRNA5—lung cancer	0.000517	0.0048	CbGpPWpGaD
Methylphenidate—SLC6A3—NRF2 pathway—NFE2L2—lung cancer	0.000504	0.00467	CbGpPWpGaD
Methylphenidate—SLC6A2—NRF2 pathway—CYP2A6—lung cancer	0.000489	0.00454	CbGpPWpGaD
Methylphenidate—SLC6A2—NRF2 pathway—GCLC—lung cancer	0.000489	0.00454	CbGpPWpGaD
Methylphenidate—SLC6A3—NRF2 pathway—TGFA—lung cancer	0.000481	0.00446	CbGpPWpGaD
Methylphenidate—SLC6A4—NRF2 pathway—NQO1—lung cancer	0.000478	0.00444	CbGpPWpGaD
Methylphenidate—SLC6A4—Circadian rythm related genes—ADCY1—lung cancer	0.000469	0.00435	CbGpPWpGaD
Methylphenidate—CYP2D6—Melatonin metabolism and effects—CYP1A1—lung cancer	0.000452	0.00419	CbGpPWpGaD
Methylphenidate—SLC6A2—Transmembrane transport of small molecules—SLC34A2—lung cancer	0.00045	0.00418	CbGpPWpGaD
Methylphenidate—SLC6A3—Alpha-synuclein signaling—SRC—lung cancer	0.00044	0.00408	CbGpPWpGaD
Methylphenidate—SLC6A3—Dopaminergic Neurogenesis—STAT3—lung cancer	0.000436	0.00404	CbGpPWpGaD
Methylphenidate—SLC6A3—NRF2 pathway—GCLC—lung cancer	0.000433	0.00402	CbGpPWpGaD
Methylphenidate—SLC6A3—NRF2 pathway—CYP2A6—lung cancer	0.000433	0.00402	CbGpPWpGaD
Methylphenidate—SLC6A3—Parkinsons Disease Pathway—CASP3—lung cancer	0.000429	0.00398	CbGpPWpGaD
Methylphenidate—SLC6A3—Neuronal System—CHRNB4—lung cancer	0.000426	0.00395	CbGpPWpGaD
Methylphenidate—SLC6A3—Transmission across Chemical Synapses—CHRNA3—lung cancer	0.000422	0.00391	CbGpPWpGaD
Methylphenidate—CYP2D6—Cytochrome P450 - arranged by substrate type—CYP2A6—lung cancer	0.000414	0.00384	CbGpPWpGaD
Methylphenidate—SLC6A2—NRF2 pathway—NQO1—lung cancer	0.000411	0.00382	CbGpPWpGaD
Methylphenidate—CYP2D6—Oxidation by Cytochrome P450—CYP2A6—lung cancer	0.000408	0.00378	CbGpPWpGaD
Methylphenidate—SLC6A4—NRF2 pathway—GSTP1—lung cancer	0.000399	0.0037	CbGpPWpGaD
Methylphenidate—SLC6A3—Transmembrane transport of small molecules—SLC34A2—lung cancer	0.000399	0.0037	CbGpPWpGaD
Methylphenidate—SLC6A3—Transmission across Chemical Synapses—GNG11—lung cancer	0.000399	0.0037	CbGpPWpGaD
Methylphenidate—SLC6A3—Neuronal System—CHRNA5—lung cancer	0.000396	0.00367	CbGpPWpGaD
Methylphenidate—SLC6A4—SIDS Susceptibility Pathways—AVP—lung cancer	0.00037	0.00343	CbGpPWpGaD
Methylphenidate—SLC6A4—NRF2 pathway—GSTM1—lung cancer	0.000367	0.0034	CbGpPWpGaD
Methylphenidate—SLC6A3—NRF2 pathway—NQO1—lung cancer	0.000364	0.00338	CbGpPWpGaD
Methylphenidate—SLC6A3—Transmission across Chemical Synapses—ADCY1—lung cancer	0.000358	0.00332	CbGpPWpGaD
Methylphenidate—CYP2D6—Cytochrome P450 - arranged by substrate type—CYP2E1—lung cancer	0.000352	0.00326	CbGpPWpGaD
Methylphenidate—SLC6A4—SIDS Susceptibility Pathways—HES1—lung cancer	0.00035	0.00324	CbGpPWpGaD
Methylphenidate—SLC6A4—SIDS Susceptibility Pathways—IL10—lung cancer	0.000348	0.00322	CbGpPWpGaD
Methylphenidate—CYP2D6—Oxidation by Cytochrome P450—CYP2E1—lung cancer	0.000347	0.00322	CbGpPWpGaD
Methylphenidate—SLC6A2—NRF2 pathway—GSTP1—lung cancer	0.000343	0.00318	CbGpPWpGaD
Methylphenidate—SLC6A2—Transmembrane transport of small molecules—SLC22A18—lung cancer	0.000341	0.00316	CbGpPWpGaD
Methylphenidate—CYP2D6—Biological oxidations—CNDP2—lung cancer	0.000339	0.00314	CbGpPWpGaD
Methylphenidate—CYP2D6—Biological oxidations—GSTM2—lung cancer	0.000339	0.00314	CbGpPWpGaD
Methylphenidate—CYP2D6—Phase 1 - Functionalization of compounds—CYP2A6—lung cancer	0.000335	0.00311	CbGpPWpGaD
Methylphenidate—CYP2D6—Metapathway biotransformation—GSTM2—lung cancer	0.000334	0.0031	CbGpPWpGaD
Methylphenidate—SLC6A3—Neuronal System—CHRNA3—lung cancer	0.000323	0.003	CbGpPWpGaD
Methylphenidate—SLC6A2—NRF2 pathway—GSTM1—lung cancer	0.000315	0.00292	CbGpPWpGaD
Methylphenidate—CYP2D6—Biological oxidations—CYP2A7—lung cancer	0.000307	0.00284	CbGpPWpGaD
Methylphenidate—SLC6A3—Neuronal System—GNG11—lung cancer	0.000305	0.00283	CbGpPWpGaD
Methylphenidate—SLC6A3—NRF2 pathway—GSTP1—lung cancer	0.000304	0.00282	CbGpPWpGaD
Methylphenidate—CYP2D6—Metapathway biotransformation—CYP2A7—lung cancer	0.000302	0.0028	CbGpPWpGaD
Methylphenidate—SLC6A3—Transmembrane transport of small molecules—SLC22A18—lung cancer	0.000302	0.0028	CbGpPWpGaD
Methylphenidate—SLC6A4—Circadian rythm related genes—AVP—lung cancer	0.000302	0.0028	CbGpPWpGaD
Methylphenidate—SLC6A4—SIDS Susceptibility Pathways—HIF1A—lung cancer	0.000293	0.00272	CbGpPWpGaD
Methylphenidate—SLC6A4—Circadian rythm related genes—TYMS—lung cancer	0.000287	0.00266	CbGpPWpGaD
Methylphenidate—CYP2D6—Phase 1 - Functionalization of compounds—CYP2E1—lung cancer	0.000285	0.00264	CbGpPWpGaD
Methylphenidate—SLC6A3—NRF2 pathway—GSTM1—lung cancer	0.000279	0.00259	CbGpPWpGaD
Methylphenidate—SLC6A3—Neuronal System—ADCY1—lung cancer	0.000275	0.00255	CbGpPWpGaD
Methylphenidate—CYP2D6—Biological oxidations—GSTA3—lung cancer	0.000273	0.00253	CbGpPWpGaD
Methylphenidate—CYP2D6—Metapathway biotransformation—GSTA3—lung cancer	0.00027	0.0025	CbGpPWpGaD
Methylphenidate—CYP2D6—Cytochrome P450 - arranged by substrate type—CYP1A1—lung cancer	0.000253	0.00234	CbGpPWpGaD
Methylphenidate—CYP2D6—Biological oxidations—GSTA4—lung cancer	0.00025	0.00232	CbGpPWpGaD
Methylphenidate—CYP2D6—Oxidation by Cytochrome P450—CYP1A1—lung cancer	0.000249	0.00231	CbGpPWpGaD
Methylphenidate—CYP2D6—Metapathway biotransformation—GSTA4—lung cancer	0.000247	0.00229	CbGpPWpGaD
Methylphenidate—CYP2D6—Biological oxidations—GSTA2—lung cancer	0.000244	0.00226	CbGpPWpGaD
Methylphenidate—SLC6A4—SIDS Susceptibility Pathways—IL6R—lung cancer	0.00024	0.00222	CbGpPWpGaD
Methylphenidate—SLC6A4—SIDS Susceptibility Pathways—CREBBP—lung cancer	0.000239	0.00222	CbGpPWpGaD
Methylphenidate—CYP2D6—Biological oxidations—GSTA1—lung cancer	0.000235	0.00218	CbGpPWpGaD
Methylphenidate—CYP2D6—Metapathway biotransformation—AKR1C1—lung cancer	0.000222	0.00206	CbGpPWpGaD
Methylphenidate—CYP2D6—Biological oxidations—UGT1A1—lung cancer	0.000218	0.00203	CbGpPWpGaD
Methylphenidate—CYP2D6—Metapathway biotransformation—UGT1A1—lung cancer	0.000215	0.002	CbGpPWpGaD
Methylphenidate—SLC6A2—SLC-mediated transmembrane transport—AVP—lung cancer	0.000211	0.00196	CbGpPWpGaD
Methylphenidate—Fatigue—Paclitaxel—lung cancer	0.000208	0.000302	CcSEcCtD
Methylphenidate—Haemorrhage—Methotrexate—lung cancer	0.000208	0.000301	CcSEcCtD
Methylphenidate—Asthenia—Gemcitabine—lung cancer	0.000207	0.0003	CcSEcCtD
Methylphenidate—Constipation—Paclitaxel—lung cancer	0.000206	0.000299	CcSEcCtD
Methylphenidate—Pain—Paclitaxel—lung cancer	0.000206	0.000299	CcSEcCtD
Methylphenidate—Confusional state—Docetaxel—lung cancer	0.000206	0.000299	CcSEcCtD
Methylphenidate—Pharyngitis—Methotrexate—lung cancer	0.000206	0.000298	CcSEcCtD
Methylphenidate—Urinary tract disorder—Methotrexate—lung cancer	0.000205	0.000297	CcSEcCtD
Methylphenidate—Photosensitivity reaction—Doxorubicin—lung cancer	0.000205	0.000297	CcSEcCtD
Methylphenidate—CYP2D6—Phase 1 - Functionalization of compounds—CYP1A1—lung cancer	0.000205	0.0019	CbGpPWpGaD
Methylphenidate—Anaphylactic shock—Docetaxel—lung cancer	0.000205	0.000296	CcSEcCtD
Methylphenidate—Oedema—Docetaxel—lung cancer	0.000205	0.000296	CcSEcCtD
Methylphenidate—SLC6A2—Transmembrane transport of small molecules—ABCC3—lung cancer	0.000204	0.0019	CbGpPWpGaD
Methylphenidate—Weight increased—Doxorubicin—lung cancer	0.000204	0.000296	CcSEcCtD
Methylphenidate—Pruritus—Gemcitabine—lung cancer	0.000204	0.000296	CcSEcCtD
Methylphenidate—Urethral disorder—Methotrexate—lung cancer	0.000203	0.000295	CcSEcCtD
Methylphenidate—Infection—Docetaxel—lung cancer	0.000203	0.000294	CcSEcCtD
Methylphenidate—Weight decreased—Doxorubicin—lung cancer	0.000203	0.000294	CcSEcCtD
Methylphenidate—Feeling abnormal—Etoposide—lung cancer	0.000203	0.000294	CcSEcCtD
Methylphenidate—Diarrhoea—Irinotecan—lung cancer	0.000203	0.000293	CcSEcCtD
Methylphenidate—Pneumonia—Doxorubicin—lung cancer	0.000201	0.000292	CcSEcCtD
Methylphenidate—Gastrointestinal pain—Etoposide—lung cancer	0.000201	0.000292	CcSEcCtD
Methylphenidate—Shock—Docetaxel—lung cancer	0.000201	0.000292	CcSEcCtD
Methylphenidate—Nervous system disorder—Docetaxel—lung cancer	0.000201	0.000291	CcSEcCtD
Methylphenidate—Thrombocytopenia—Docetaxel—lung cancer	0.0002	0.00029	CcSEcCtD
Methylphenidate—Infestation—Doxorubicin—lung cancer	0.0002	0.00029	CcSEcCtD
Methylphenidate—Infestation NOS—Doxorubicin—lung cancer	0.0002	0.00029	CcSEcCtD
Methylphenidate—Drowsiness—Doxorubicin—lung cancer	0.0002	0.00029	CcSEcCtD
Methylphenidate—Visual impairment—Methotrexate—lung cancer	0.0002	0.00029	CcSEcCtD
Methylphenidate—Tachycardia—Docetaxel—lung cancer	0.0002	0.000289	CcSEcCtD
Methylphenidate—Feeling abnormal—Paclitaxel—lung cancer	0.000199	0.000288	CcSEcCtD
Methylphenidate—Skin disorder—Docetaxel—lung cancer	0.000199	0.000288	CcSEcCtD
Methylphenidate—Stevens-Johnson syndrome—Doxorubicin—lung cancer	0.000199	0.000288	CcSEcCtD
Methylphenidate—Hypersensitivity—Cisplatin—lung cancer	0.000198	0.000287	CcSEcCtD
Methylphenidate—Gastrointestinal pain—Paclitaxel—lung cancer	0.000197	0.000286	CcSEcCtD
Methylphenidate—Diarrhoea—Gemcitabine—lung cancer	0.000197	0.000286	CcSEcCtD
Methylphenidate—Erythema multiforme—Methotrexate—lung cancer	0.000196	0.000284	CcSEcCtD
Methylphenidate—Dizziness—Irinotecan—lung cancer	0.000196	0.000284	CcSEcCtD
Methylphenidate—Urticaria—Etoposide—lung cancer	0.000196	0.000283	CcSEcCtD
Methylphenidate—Anorexia—Docetaxel—lung cancer	0.000195	0.000283	CcSEcCtD
Methylphenidate—Abdominal pain—Etoposide—lung cancer	0.000195	0.000282	CcSEcCtD
Methylphenidate—Body temperature increased—Etoposide—lung cancer	0.000195	0.000282	CcSEcCtD
Methylphenidate—Conjunctivitis—Doxorubicin—lung cancer	0.000195	0.000282	CcSEcCtD
Methylphenidate—Eye disorder—Methotrexate—lung cancer	0.000194	0.000281	CcSEcCtD
Methylphenidate—Asthenia—Cisplatin—lung cancer	0.000193	0.000279	CcSEcCtD
Methylphenidate—Cardiac disorder—Methotrexate—lung cancer	0.000193	0.000279	CcSEcCtD
Methylphenidate—Sweating—Doxorubicin—lung cancer	0.000192	0.000278	CcSEcCtD
Methylphenidate—Urticaria—Paclitaxel—lung cancer	0.000192	0.000278	CcSEcCtD
Methylphenidate—Haematuria—Doxorubicin—lung cancer	0.000191	0.000277	CcSEcCtD
Methylphenidate—Abdominal pain—Paclitaxel—lung cancer	0.000191	0.000276	CcSEcCtD
Methylphenidate—Body temperature increased—Paclitaxel—lung cancer	0.000191	0.000276	CcSEcCtD
Methylphenidate—SLC6A4—SIDS Susceptibility Pathways—CXCL8—lung cancer	0.00019	0.00176	CbGpPWpGaD
Methylphenidate—Hepatobiliary disease—Doxorubicin—lung cancer	0.000189	0.000274	CcSEcCtD
Methylphenidate—Epistaxis—Doxorubicin—lung cancer	0.000189	0.000274	CcSEcCtD
Methylphenidate—CYP2D6—Cytochrome P450 - arranged by substrate type—POMC—lung cancer	0.000188	0.00175	CbGpPWpGaD
Methylphenidate—Angiopathy—Methotrexate—lung cancer	0.000188	0.000273	CcSEcCtD
Methylphenidate—Vomiting—Irinotecan—lung cancer	0.000188	0.000273	CcSEcCtD
Methylphenidate—Sinusitis—Doxorubicin—lung cancer	0.000188	0.000272	CcSEcCtD
Methylphenidate—Immune system disorder—Methotrexate—lung cancer	0.000187	0.000272	CcSEcCtD
Methylphenidate—SLC6A3—SLC-mediated transmembrane transport—AVP—lung cancer	0.000187	0.00174	CbGpPWpGaD
Methylphenidate—Mediastinal disorder—Methotrexate—lung cancer	0.000187	0.000271	CcSEcCtD
Methylphenidate—Rash—Irinotecan—lung cancer	0.000187	0.00027	CcSEcCtD
Methylphenidate—Dermatitis—Irinotecan—lung cancer	0.000186	0.00027	CcSEcCtD
Methylphenidate—Musculoskeletal discomfort—Docetaxel—lung cancer	0.000186	0.00027	CcSEcCtD
Methylphenidate—Chills—Methotrexate—lung cancer	0.000186	0.00027	CcSEcCtD
Methylphenidate—CYP2D6—Biological oxidations—HPGDS—lung cancer	0.000186	0.00172	CbGpPWpGaD
Methylphenidate—Headache—Irinotecan—lung cancer	0.000185	0.000269	CcSEcCtD
Methylphenidate—SLC6A2—Transmembrane transport of small molecules—GNG11—lung cancer	0.000185	0.00172	CbGpPWpGaD
Methylphenidate—Insomnia—Docetaxel—lung cancer	0.000185	0.000268	CcSEcCtD
Methylphenidate—Diarrhoea—Cisplatin—lung cancer	0.000184	0.000266	CcSEcCtD
Methylphenidate—Paraesthesia—Docetaxel—lung cancer	0.000184	0.000266	CcSEcCtD
Methylphenidate—Alopecia—Methotrexate—lung cancer	0.000183	0.000266	CcSEcCtD
Methylphenidate—Vomiting—Gemcitabine—lung cancer	0.000183	0.000266	CcSEcCtD
Methylphenidate—Bradycardia—Doxorubicin—lung cancer	0.000183	0.000265	CcSEcCtD
Methylphenidate—Dyspnoea—Docetaxel—lung cancer	0.000182	0.000264	CcSEcCtD
Methylphenidate—SLC6A4—SIDS Susceptibility Pathways—CASP3—lung cancer	0.000182	0.00169	CbGpPWpGaD
Methylphenidate—Somnolence—Docetaxel—lung cancer	0.000182	0.000264	CcSEcCtD
Methylphenidate—Mental disorder—Methotrexate—lung cancer	0.000182	0.000263	CcSEcCtD
Methylphenidate—Rash—Gemcitabine—lung cancer	0.000182	0.000263	CcSEcCtD
Methylphenidate—Dermatitis—Gemcitabine—lung cancer	0.000182	0.000263	CcSEcCtD
Methylphenidate—Hypersensitivity—Etoposide—lung cancer	0.000181	0.000263	CcSEcCtD
Methylphenidate—SLC6A3—Transmembrane transport of small molecules—ABCC3—lung cancer	0.000181	0.00168	CbGpPWpGaD
Methylphenidate—Erythema—Methotrexate—lung cancer	0.000181	0.000262	CcSEcCtD
Methylphenidate—Malnutrition—Methotrexate—lung cancer	0.000181	0.000262	CcSEcCtD
Methylphenidate—Haemoglobin—Doxorubicin—lung cancer	0.000181	0.000262	CcSEcCtD
Methylphenidate—Headache—Gemcitabine—lung cancer	0.000181	0.000262	CcSEcCtD
Methylphenidate—Rhinitis—Doxorubicin—lung cancer	0.00018	0.000261	CcSEcCtD
Methylphenidate—CYP2D6—Biological oxidations—GSTT1—lung cancer	0.00018	0.00167	CbGpPWpGaD
Methylphenidate—Dyspepsia—Docetaxel—lung cancer	0.00018	0.000261	CcSEcCtD
Methylphenidate—Haemorrhage—Doxorubicin—lung cancer	0.00018	0.00026	CcSEcCtD
Methylphenidate—Pharyngitis—Doxorubicin—lung cancer	0.000178	0.000258	CcSEcCtD
Methylphenidate—CYP2D6—Biological oxidations—CYP2A6—lung cancer	0.000178	0.00165	CbGpPWpGaD
Methylphenidate—CYP2D6—Biological oxidations—GCLC—lung cancer	0.000178	0.00165	CbGpPWpGaD
Methylphenidate—Decreased appetite—Docetaxel—lung cancer	0.000178	0.000258	CcSEcCtD
Methylphenidate—Hypersensitivity—Paclitaxel—lung cancer	0.000178	0.000258	CcSEcCtD
Methylphenidate—Urinary tract disorder—Doxorubicin—lung cancer	0.000178	0.000257	CcSEcCtD
Methylphenidate—SLC6A4—SIDS Susceptibility Pathways—JUN—lung cancer	0.000177	0.00164	CbGpPWpGaD
Methylphenidate—Gastrointestinal disorder—Docetaxel—lung cancer	0.000177	0.000256	CcSEcCtD
Methylphenidate—Asthenia—Etoposide—lung cancer	0.000177	0.000256	CcSEcCtD
Methylphenidate—Connective tissue disorder—Doxorubicin—lung cancer	0.000177	0.000256	CcSEcCtD
Methylphenidate—Fatigue—Docetaxel—lung cancer	0.000176	0.000256	CcSEcCtD
Methylphenidate—Urethral disorder—Doxorubicin—lung cancer	0.000176	0.000255	CcSEcCtD
Methylphenidate—Nausea—Irinotecan—lung cancer	0.000176	0.000255	CcSEcCtD
Methylphenidate—Pain—Docetaxel—lung cancer	0.000175	0.000253	CcSEcCtD
Methylphenidate—Constipation—Docetaxel—lung cancer	0.000175	0.000253	CcSEcCtD
Methylphenidate—Back pain—Methotrexate—lung cancer	0.000175	0.000253	CcSEcCtD
Methylphenidate—Pruritus—Etoposide—lung cancer	0.000174	0.000252	CcSEcCtD
Methylphenidate—Visual impairment—Doxorubicin—lung cancer	0.000173	0.000251	CcSEcCtD
Methylphenidate—Asthenia—Paclitaxel—lung cancer	0.000173	0.000251	CcSEcCtD
Methylphenidate—Nausea—Gemcitabine—lung cancer	0.000171	0.000248	CcSEcCtD
Methylphenidate—Vomiting—Cisplatin—lung cancer	0.000171	0.000248	CcSEcCtD
Methylphenidate—Pruritus—Paclitaxel—lung cancer	0.000171	0.000247	CcSEcCtD
Methylphenidate—Vision blurred—Methotrexate—lung cancer	0.00017	0.000247	CcSEcCtD
Methylphenidate—Erythema multiforme—Doxorubicin—lung cancer	0.00017	0.000246	CcSEcCtD
Methylphenidate—Rash—Cisplatin—lung cancer	0.000169	0.000245	CcSEcCtD
Methylphenidate—Dermatitis—Cisplatin—lung cancer	0.000169	0.000245	CcSEcCtD
Methylphenidate—Feeling abnormal—Docetaxel—lung cancer	0.000169	0.000244	CcSEcCtD
Methylphenidate—Diarrhoea—Etoposide—lung cancer	0.000168	0.000244	CcSEcCtD
Methylphenidate—Eye disorder—Doxorubicin—lung cancer	0.000168	0.000243	CcSEcCtD
Methylphenidate—Ill-defined disorder—Methotrexate—lung cancer	0.000168	0.000243	CcSEcCtD
Methylphenidate—Gastrointestinal pain—Docetaxel—lung cancer	0.000167	0.000242	CcSEcCtD
Methylphenidate—Anaemia—Methotrexate—lung cancer	0.000167	0.000242	CcSEcCtD
Methylphenidate—Cardiac disorder—Doxorubicin—lung cancer	0.000167	0.000242	CcSEcCtD
Methylphenidate—Flushing—Doxorubicin—lung cancer	0.000167	0.000242	CcSEcCtD
Methylphenidate—SLC6A2—Transmembrane transport of small molecules—ADCY1—lung cancer	0.000167	0.00155	CbGpPWpGaD
Methylphenidate—SLC6A2—Transmembrane transport of small molecules—ABCG2—lung cancer	0.000167	0.00155	CbGpPWpGaD
Methylphenidate—Diarrhoea—Paclitaxel—lung cancer	0.000165	0.000239	CcSEcCtD
Methylphenidate—SLC6A3—Transmembrane transport of small molecules—GNG11—lung cancer	0.000164	0.00152	CbGpPWpGaD
Methylphenidate—Angiopathy—Doxorubicin—lung cancer	0.000163	0.000236	CcSEcCtD
Methylphenidate—SLC6A4—SIDS Susceptibility Pathways—EP300—lung cancer	0.000163	0.00151	CbGpPWpGaD
Methylphenidate—Malaise—Methotrexate—lung cancer	0.000163	0.000236	CcSEcCtD
Methylphenidate—Dizziness—Etoposide—lung cancer	0.000163	0.000236	CcSEcCtD
Methylphenidate—Immune system disorder—Doxorubicin—lung cancer	0.000162	0.000235	CcSEcCtD
Methylphenidate—Vertigo—Methotrexate—lung cancer	0.000162	0.000235	CcSEcCtD
Methylphenidate—Mediastinal disorder—Doxorubicin—lung cancer	0.000162	0.000235	CcSEcCtD
Methylphenidate—Body temperature increased—Docetaxel—lung cancer	0.000162	0.000234	CcSEcCtD
Methylphenidate—Abdominal pain—Docetaxel—lung cancer	0.000162	0.000234	CcSEcCtD
Methylphenidate—Leukopenia—Methotrexate—lung cancer	0.000162	0.000234	CcSEcCtD
Methylphenidate—Chills—Doxorubicin—lung cancer	0.000161	0.000234	CcSEcCtD
Methylphenidate—Arrhythmia—Doxorubicin—lung cancer	0.000161	0.000233	CcSEcCtD
Methylphenidate—Dizziness—Paclitaxel—lung cancer	0.00016	0.000231	CcSEcCtD
Methylphenidate—Nausea—Cisplatin—lung cancer	0.00016	0.000231	CcSEcCtD
Methylphenidate—Alopecia—Doxorubicin—lung cancer	0.000159	0.00023	CcSEcCtD
Methylphenidate—Cough—Methotrexate—lung cancer	0.000158	0.000228	CcSEcCtD
Methylphenidate—Mental disorder—Doxorubicin—lung cancer	0.000157	0.000228	CcSEcCtD
Methylphenidate—Convulsion—Methotrexate—lung cancer	0.000157	0.000227	CcSEcCtD
Methylphenidate—Vomiting—Etoposide—lung cancer	0.000157	0.000227	CcSEcCtD
Methylphenidate—Malnutrition—Doxorubicin—lung cancer	0.000156	0.000227	CcSEcCtD
Methylphenidate—Erythema—Doxorubicin—lung cancer	0.000156	0.000227	CcSEcCtD
Methylphenidate—Rash—Etoposide—lung cancer	0.000155	0.000225	CcSEcCtD
Methylphenidate—Dermatitis—Etoposide—lung cancer	0.000155	0.000225	CcSEcCtD
Methylphenidate—SLC6A2—Transmembrane transport of small molecules—TF—lung cancer	0.000155	0.00144	CbGpPWpGaD
Methylphenidate—SLC6A4—SIDS Susceptibility Pathways—VEGFA—lung cancer	0.000154	0.00143	CbGpPWpGaD
Methylphenidate—Headache—Etoposide—lung cancer	0.000154	0.000223	CcSEcCtD
Methylphenidate—Myalgia—Methotrexate—lung cancer	0.000154	0.000223	CcSEcCtD
Methylphenidate—Arthralgia—Methotrexate—lung cancer	0.000154	0.000223	CcSEcCtD
Methylphenidate—Chest pain—Methotrexate—lung cancer	0.000154	0.000223	CcSEcCtD
Methylphenidate—Tension—Doxorubicin—lung cancer	0.000154	0.000222	CcSEcCtD
Methylphenidate—Vomiting—Paclitaxel—lung cancer	0.000153	0.000222	CcSEcCtD
Methylphenidate—Unspecified disorder of skin and subcutaneous tissue—Methotrexate—lung cancer	0.000153	0.000221	CcSEcCtD
Methylphenidate—CYP2D6—Phase 1 - Functionalization of compounds—POMC—lung cancer	0.000153	0.00142	CbGpPWpGaD
Methylphenidate—Rash—Paclitaxel—lung cancer	0.000152	0.000221	CcSEcCtD
Methylphenidate—Dermatitis—Paclitaxel—lung cancer	0.000152	0.00022	CcSEcCtD
Methylphenidate—Discomfort—Methotrexate—lung cancer	0.000152	0.00022	CcSEcCtD
Methylphenidate—Nervousness—Doxorubicin—lung cancer	0.000152	0.00022	CcSEcCtD
Methylphenidate—SLC6A3—Transmission across Chemical Synapses—BRAF—lung cancer	0.000152	0.00141	CbGpPWpGaD
Methylphenidate—CYP2D6—Biological oxidations—CYP2E1—lung cancer	0.000151	0.0014	CbGpPWpGaD
Methylphenidate—Back pain—Doxorubicin—lung cancer	0.000151	0.000219	CcSEcCtD
Methylphenidate—Headache—Paclitaxel—lung cancer	0.000151	0.000219	CcSEcCtD
Methylphenidate—Hypersensitivity—Docetaxel—lung cancer	0.000151	0.000218	CcSEcCtD
Methylphenidate—Muscle spasms—Doxorubicin—lung cancer	0.00015	0.000218	CcSEcCtD
Methylphenidate—CYP2D6—Metapathway biotransformation—CYP2E1—lung cancer	0.000149	0.00139	CbGpPWpGaD
Methylphenidate—Confusional state—Methotrexate—lung cancer	0.000149	0.000215	CcSEcCtD
Methylphenidate—SLC6A3—Transmembrane transport of small molecules—ADCY1—lung cancer	0.000148	0.00137	CbGpPWpGaD
Methylphenidate—SLC6A3—Transmembrane transport of small molecules—ABCG2—lung cancer	0.000148	0.00137	CbGpPWpGaD
Methylphenidate—Anaphylactic shock—Methotrexate—lung cancer	0.000147	0.000214	CcSEcCtD
Methylphenidate—Vision blurred—Doxorubicin—lung cancer	0.000147	0.000214	CcSEcCtD
Methylphenidate—Asthenia—Docetaxel—lung cancer	0.000147	0.000213	CcSEcCtD
Methylphenidate—Infection—Methotrexate—lung cancer	0.000147	0.000212	CcSEcCtD
Methylphenidate—Nausea—Etoposide—lung cancer	0.000146	0.000212	CcSEcCtD
Methylphenidate—Ill-defined disorder—Doxorubicin—lung cancer	0.000145	0.00021	CcSEcCtD
Methylphenidate—Pruritus—Docetaxel—lung cancer	0.000145	0.00021	CcSEcCtD
Methylphenidate—Nervous system disorder—Methotrexate—lung cancer	0.000145	0.00021	CcSEcCtD
Methylphenidate—Anaemia—Doxorubicin—lung cancer	0.000145	0.00021	CcSEcCtD
Methylphenidate—Thrombocytopenia—Methotrexate—lung cancer	0.000144	0.000209	CcSEcCtD
Methylphenidate—SLC6A4—Circadian rythm related genes—JUN—lung cancer	0.000144	0.00134	CbGpPWpGaD
Methylphenidate—Agitation—Doxorubicin—lung cancer	0.000144	0.000208	CcSEcCtD
Methylphenidate—Nausea—Paclitaxel—lung cancer	0.000143	0.000208	CcSEcCtD
Methylphenidate—Skin disorder—Methotrexate—lung cancer	0.000143	0.000208	CcSEcCtD
Methylphenidate—Hyperhidrosis—Methotrexate—lung cancer	0.000143	0.000207	CcSEcCtD
Methylphenidate—Malaise—Doxorubicin—lung cancer	0.000141	0.000204	CcSEcCtD
Methylphenidate—Vertigo—Doxorubicin—lung cancer	0.000141	0.000204	CcSEcCtD
Methylphenidate—Anorexia—Methotrexate—lung cancer	0.000141	0.000204	CcSEcCtD
Methylphenidate—Syncope—Doxorubicin—lung cancer	0.00014	0.000203	CcSEcCtD
Methylphenidate—Leukopenia—Doxorubicin—lung cancer	0.00014	0.000203	CcSEcCtD
Methylphenidate—Diarrhoea—Docetaxel—lung cancer	0.00014	0.000203	CcSEcCtD
Methylphenidate—SLC6A4—Circadian rythm related genes—PTEN—lung cancer	0.00014	0.00129	CbGpPWpGaD
Methylphenidate—Palpitations—Doxorubicin—lung cancer	0.000138	0.0002	CcSEcCtD
Methylphenidate—Loss of consciousness—Doxorubicin—lung cancer	0.000138	0.000199	CcSEcCtD
Methylphenidate—SLC6A3—Transmembrane transport of small molecules—TF—lung cancer	0.000137	0.00127	CbGpPWpGaD
Methylphenidate—Cough—Doxorubicin—lung cancer	0.000137	0.000198	CcSEcCtD
Methylphenidate—Convulsion—Doxorubicin—lung cancer	0.000136	0.000196	CcSEcCtD
Methylphenidate—Dizziness—Docetaxel—lung cancer	0.000135	0.000196	CcSEcCtD
Methylphenidate—Hypertension—Doxorubicin—lung cancer	0.000135	0.000196	CcSEcCtD
Methylphenidate—Musculoskeletal discomfort—Methotrexate—lung cancer	0.000134	0.000195	CcSEcCtD
Methylphenidate—Insomnia—Methotrexate—lung cancer	0.000133	0.000193	CcSEcCtD
Methylphenidate—Myalgia—Doxorubicin—lung cancer	0.000133	0.000193	CcSEcCtD
Methylphenidate—Arthralgia—Doxorubicin—lung cancer	0.000133	0.000193	CcSEcCtD
Methylphenidate—Chest pain—Doxorubicin—lung cancer	0.000133	0.000193	CcSEcCtD
Methylphenidate—SLC6A4—Circadian rythm related genes—EP300—lung cancer	0.000133	0.00123	CbGpPWpGaD
Methylphenidate—Anxiety—Doxorubicin—lung cancer	0.000133	0.000192	CcSEcCtD
Methylphenidate—Paraesthesia—Methotrexate—lung cancer	0.000132	0.000192	CcSEcCtD
Methylphenidate—Unspecified disorder of skin and subcutaneous tissue—Doxorubicin—lung cancer	0.000132	0.000192	CcSEcCtD
Methylphenidate—Discomfort—Doxorubicin—lung cancer	0.000132	0.000191	CcSEcCtD
Methylphenidate—Dyspnoea—Methotrexate—lung cancer	0.000131	0.00019	CcSEcCtD
Methylphenidate—Somnolence—Methotrexate—lung cancer	0.000131	0.00019	CcSEcCtD
Methylphenidate—Dry mouth—Doxorubicin—lung cancer	0.00013	0.000189	CcSEcCtD
Methylphenidate—Vomiting—Docetaxel—lung cancer	0.00013	0.000188	CcSEcCtD
Methylphenidate—Dyspepsia—Methotrexate—lung cancer	0.00013	0.000188	CcSEcCtD
Methylphenidate—Rash—Docetaxel—lung cancer	0.000129	0.000187	CcSEcCtD
Methylphenidate—Dermatitis—Docetaxel—lung cancer	0.000129	0.000187	CcSEcCtD
Methylphenidate—Confusional state—Doxorubicin—lung cancer	0.000129	0.000187	CcSEcCtD
Methylphenidate—Decreased appetite—Methotrexate—lung cancer	0.000128	0.000186	CcSEcCtD
Methylphenidate—Headache—Docetaxel—lung cancer	0.000128	0.000186	CcSEcCtD
Methylphenidate—SLC6A2—SLC-mediated transmembrane transport—ALB—lung cancer	0.000128	0.00119	CbGpPWpGaD
Methylphenidate—Anaphylactic shock—Doxorubicin—lung cancer	0.000128	0.000185	CcSEcCtD
Methylphenidate—Oedema—Doxorubicin—lung cancer	0.000128	0.000185	CcSEcCtD
Methylphenidate—Gastrointestinal disorder—Methotrexate—lung cancer	0.000127	0.000184	CcSEcCtD
Methylphenidate—Fatigue—Methotrexate—lung cancer	0.000127	0.000184	CcSEcCtD
Methylphenidate—SLC6A3—Transmission across Chemical Synapses—MDM2—lung cancer	0.000127	0.00118	CbGpPWpGaD
Methylphenidate—Infection—Doxorubicin—lung cancer	0.000127	0.000184	CcSEcCtD
Methylphenidate—SLC6A3—Transmission across Chemical Synapses—RAF1—lung cancer	0.000127	0.00117	CbGpPWpGaD
Methylphenidate—Pain—Methotrexate—lung cancer	0.000126	0.000183	CcSEcCtD
Methylphenidate—Shock—Doxorubicin—lung cancer	0.000126	0.000182	CcSEcCtD
Methylphenidate—Nervous system disorder—Doxorubicin—lung cancer	0.000125	0.000181	CcSEcCtD
Methylphenidate—Thrombocytopenia—Doxorubicin—lung cancer	0.000125	0.000181	CcSEcCtD
Methylphenidate—CYP2D6—Biological oxidations—GSTP1—lung cancer	0.000125	0.00116	CbGpPWpGaD
Methylphenidate—Tachycardia—Doxorubicin—lung cancer	0.000125	0.000181	CcSEcCtD
Methylphenidate—Skin disorder—Doxorubicin—lung cancer	0.000124	0.00018	CcSEcCtD
Methylphenidate—Hyperhidrosis—Doxorubicin—lung cancer	0.000123	0.000179	CcSEcCtD
Methylphenidate—CYP2D6—Metapathway biotransformation—GSTP1—lung cancer	0.000123	0.00114	CbGpPWpGaD
Methylphenidate—Anorexia—Doxorubicin—lung cancer	0.000122	0.000176	CcSEcCtD
Methylphenidate—Nausea—Docetaxel—lung cancer	0.000122	0.000176	CcSEcCtD
Methylphenidate—Feeling abnormal—Methotrexate—lung cancer	0.000122	0.000176	CcSEcCtD
Methylphenidate—Gastrointestinal pain—Methotrexate—lung cancer	0.000121	0.000175	CcSEcCtD
Methylphenidate—Urticaria—Methotrexate—lung cancer	0.000117	0.00017	CcSEcCtD
Methylphenidate—Body temperature increased—Methotrexate—lung cancer	0.000117	0.000169	CcSEcCtD
Methylphenidate—Abdominal pain—Methotrexate—lung cancer	0.000117	0.000169	CcSEcCtD
Methylphenidate—Musculoskeletal discomfort—Doxorubicin—lung cancer	0.000116	0.000169	CcSEcCtD
Methylphenidate—SLC6A3—Neuronal System—BRAF—lung cancer	0.000116	0.00108	CbGpPWpGaD
Methylphenidate—Insomnia—Doxorubicin—lung cancer	0.000115	0.000167	CcSEcCtD
Methylphenidate—CYP2D6—Biological oxidations—GSTM1—lung cancer	0.000115	0.00106	CbGpPWpGaD
Methylphenidate—Paraesthesia—Doxorubicin—lung cancer	0.000115	0.000166	CcSEcCtD
Methylphenidate—Dyspnoea—Doxorubicin—lung cancer	0.000114	0.000165	CcSEcCtD
Methylphenidate—Somnolence—Doxorubicin—lung cancer	0.000114	0.000164	CcSEcCtD
Methylphenidate—SLC6A3—SLC-mediated transmembrane transport—ALB—lung cancer	0.000113	0.00105	CbGpPWpGaD
Methylphenidate—CYP2D6—Metapathway biotransformation—GSTM1—lung cancer	0.000113	0.00105	CbGpPWpGaD
Methylphenidate—Dyspepsia—Doxorubicin—lung cancer	0.000112	0.000163	CcSEcCtD
Methylphenidate—Decreased appetite—Doxorubicin—lung cancer	0.000111	0.000161	CcSEcCtD
Methylphenidate—Gastrointestinal disorder—Doxorubicin—lung cancer	0.00011	0.00016	CcSEcCtD
Methylphenidate—Fatigue—Doxorubicin—lung cancer	0.00011	0.00016	CcSEcCtD
Methylphenidate—Pain—Doxorubicin—lung cancer	0.000109	0.000158	CcSEcCtD
Methylphenidate—Constipation—Doxorubicin—lung cancer	0.000109	0.000158	CcSEcCtD
Methylphenidate—CYP2D6—Biological oxidations—CYP1A1—lung cancer	0.000109	0.00101	CbGpPWpGaD
Methylphenidate—Hypersensitivity—Methotrexate—lung cancer	0.000109	0.000157	CcSEcCtD
Methylphenidate—SLC6A2—Transmembrane transport of small molecules—AVP—lung cancer	0.000107	0.000996	CbGpPWpGaD
Methylphenidate—CYP2D6—Metapathway biotransformation—CYP1A1—lung cancer	0.000107	0.000995	CbGpPWpGaD
Methylphenidate—SLC6A4—SIDS Susceptibility Pathways—IL6—lung cancer	0.000107	0.00099	CbGpPWpGaD
Methylphenidate—Asthenia—Methotrexate—lung cancer	0.000106	0.000153	CcSEcCtD
Methylphenidate—Feeling abnormal—Doxorubicin—lung cancer	0.000105	0.000152	CcSEcCtD
Methylphenidate—Gastrointestinal pain—Doxorubicin—lung cancer	0.000104	0.000151	CcSEcCtD
Methylphenidate—Pruritus—Methotrexate—lung cancer	0.000104	0.000151	CcSEcCtD
Methylphenidate—SLC6A2—Transmembrane transport of small molecules—ABCB1—lung cancer	0.000104	0.000965	CbGpPWpGaD
Methylphenidate—Urticaria—Doxorubicin—lung cancer	0.000101	0.000147	CcSEcCtD
Methylphenidate—Body temperature increased—Doxorubicin—lung cancer	0.000101	0.000146	CcSEcCtD
Methylphenidate—Abdominal pain—Doxorubicin—lung cancer	0.000101	0.000146	CcSEcCtD
Methylphenidate—Diarrhoea—Methotrexate—lung cancer	0.000101	0.000146	CcSEcCtD
Methylphenidate—Dizziness—Methotrexate—lung cancer	9.75e-05	0.000141	CcSEcCtD
Methylphenidate—SLC6A3—Neuronal System—MDM2—lung cancer	9.73e-05	0.000902	CbGpPWpGaD
Methylphenidate—SLC6A3—Neuronal System—RAF1—lung cancer	9.7e-05	0.000899	CbGpPWpGaD
Methylphenidate—CYP2D6—Metabolism—COL4A3BP—lung cancer	9.57e-05	0.000887	CbGpPWpGaD
Methylphenidate—CYP2D6—Metabolism—AZIN2—lung cancer	9.57e-05	0.000887	CbGpPWpGaD
Methylphenidate—SLC6A4—Circadian rythm related genes—TP53—lung cancer	9.53e-05	0.000883	CbGpPWpGaD
Methylphenidate—SLC6A3—Transmembrane transport of small molecules—AVP—lung cancer	9.51e-05	0.000882	CbGpPWpGaD
Methylphenidate—Hypersensitivity—Doxorubicin—lung cancer	9.41e-05	0.000136	CcSEcCtD
Methylphenidate—Vomiting—Methotrexate—lung cancer	9.38e-05	0.000136	CcSEcCtD
Methylphenidate—Rash—Methotrexate—lung cancer	9.3e-05	0.000135	CcSEcCtD
Methylphenidate—Dermatitis—Methotrexate—lung cancer	9.29e-05	0.000135	CcSEcCtD
Methylphenidate—Headache—Methotrexate—lung cancer	9.24e-05	0.000134	CcSEcCtD
Methylphenidate—SLC6A3—Transmembrane transport of small molecules—ABCB1—lung cancer	9.21e-05	0.000855	CbGpPWpGaD
Methylphenidate—Asthenia—Doxorubicin—lung cancer	9.16e-05	0.000133	CcSEcCtD
Methylphenidate—Pruritus—Doxorubicin—lung cancer	9.03e-05	0.000131	CcSEcCtD
Methylphenidate—Nausea—Methotrexate—lung cancer	8.76e-05	0.000127	CcSEcCtD
Methylphenidate—Diarrhoea—Doxorubicin—lung cancer	8.74e-05	0.000127	CcSEcCtD
Methylphenidate—SLC6A4—Circadian rythm related genes—IL6—lung cancer	8.72e-05	0.000809	CbGpPWpGaD
Methylphenidate—Dizziness—Doxorubicin—lung cancer	8.44e-05	0.000122	CcSEcCtD
Methylphenidate—SLC6A2—Transmembrane transport of small molecules—APOA1—lung cancer	8.21e-05	0.000762	CbGpPWpGaD
Methylphenidate—CYP2D6—Metabolism—ATP5H—lung cancer	8.14e-05	0.000755	CbGpPWpGaD
Methylphenidate—Vomiting—Doxorubicin—lung cancer	8.12e-05	0.000118	CcSEcCtD
Methylphenidate—CYP2D6—Biological oxidations—POMC—lung cancer	8.11e-05	0.000752	CbGpPWpGaD
Methylphenidate—Rash—Doxorubicin—lung cancer	8.05e-05	0.000117	CcSEcCtD
Methylphenidate—Dermatitis—Doxorubicin—lung cancer	8.04e-05	0.000117	CcSEcCtD
Methylphenidate—Headache—Doxorubicin—lung cancer	8e-05	0.000116	CcSEcCtD
Methylphenidate—Nausea—Doxorubicin—lung cancer	7.59e-05	0.00011	CcSEcCtD
Methylphenidate—SLC6A3—Transmembrane transport of small molecules—APOA1—lung cancer	7.28e-05	0.000675	CbGpPWpGaD
Methylphenidate—CYP2D6—Metabolism—PLBD1—lung cancer	7.25e-05	0.000673	CbGpPWpGaD
Methylphenidate—SLC6A3—Transmission across Chemical Synapses—HRAS—lung cancer	6.97e-05	0.000646	CbGpPWpGaD
Methylphenidate—SLC6A2—Transmembrane transport of small molecules—CREBBP—lung cancer	6.95e-05	0.000645	CbGpPWpGaD
Methylphenidate—CYP2D6—Metabolism—HSD17B10—lung cancer	6.63e-05	0.000615	CbGpPWpGaD
Methylphenidate—SLC6A2—Transmembrane transport of small molecules—ALB—lung cancer	6.51e-05	0.000603	CbGpPWpGaD
Methylphenidate—CYP2D6—Metabolism—CKB—lung cancer	6.17e-05	0.000572	CbGpPWpGaD
Methylphenidate—SLC6A3—Transmembrane transport of small molecules—CREBBP—lung cancer	6.16e-05	0.000571	CbGpPWpGaD
Methylphenidate—SLC6A2—Transmembrane transport of small molecules—RAF1—lung cancer	5.88e-05	0.000546	CbGpPWpGaD
Methylphenidate—CYP2D6—Metabolism—GSTM2—lung cancer	5.8e-05	0.000538	CbGpPWpGaD
Methylphenidate—CYP2D6—Metabolism—CNDP2—lung cancer	5.8e-05	0.000538	CbGpPWpGaD
Methylphenidate—SLC6A3—Transmembrane transport of small molecules—ALB—lung cancer	5.76e-05	0.000535	CbGpPWpGaD
Methylphenidate—CYP2D6—Metabolism—MTMR3—lung cancer	5.64e-05	0.000523	CbGpPWpGaD
Methylphenidate—CYP2D6—Metabolism—PGAM1—lung cancer	5.5e-05	0.00051	CbGpPWpGaD
Methylphenidate—SLC6A3—Neuronal System—HRAS—lung cancer	5.34e-05	0.000495	CbGpPWpGaD
Methylphenidate—CYP2D6—Metabolism—CYP2A7—lung cancer	5.24e-05	0.000486	CbGpPWpGaD
Methylphenidate—SLC6A3—Transmembrane transport of small molecules—RAF1—lung cancer	5.21e-05	0.000483	CbGpPWpGaD
Methylphenidate—CYP2D6—Metabolism—SDC4—lung cancer	5.13e-05	0.000476	CbGpPWpGaD
Methylphenidate—CYP2D6—Metabolism—GSTA3—lung cancer	4.67e-05	0.000433	CbGpPWpGaD
Methylphenidate—CYP2D6—Metabolism—RRM1—lung cancer	4.67e-05	0.000433	CbGpPWpGaD
Methylphenidate—CYP2D6—Metabolism—B4GALT5—lung cancer	4.39e-05	0.000407	CbGpPWpGaD
Methylphenidate—CYP2D6—Metabolism—GSTA4—lung cancer	4.27e-05	0.000396	CbGpPWpGaD
Methylphenidate—CYP2D6—Metabolism—GSTA2—lung cancer	4.17e-05	0.000386	CbGpPWpGaD
Methylphenidate—CYP2D6—Metabolism—GSTA1—lung cancer	4.02e-05	0.000373	CbGpPWpGaD
Methylphenidate—CYP2D6—Metabolism—ABCC3—lung cancer	3.97e-05	0.000369	CbGpPWpGaD
Methylphenidate—CYP2D6—Metabolism—AKR1C1—lung cancer	3.85e-05	0.000357	CbGpPWpGaD
Methylphenidate—CYP2D6—Metabolism—UGT1A1—lung cancer	3.74e-05	0.000346	CbGpPWpGaD
Methylphenidate—CYP2D6—Metabolism—GNG11—lung cancer	3.6e-05	0.000334	CbGpPWpGaD
Methylphenidate—CYP2D6—Metabolism—ALDOA—lung cancer	3.43e-05	0.000318	CbGpPWpGaD
Methylphenidate—CYP2D6—Metabolism—NCOA3—lung cancer	3.33e-05	0.000309	CbGpPWpGaD
Methylphenidate—CYP2D6—Metabolism—ADCY1—lung cancer	3.24e-05	0.0003	CbGpPWpGaD
Methylphenidate—CYP2D6—Metabolism—ABCG2—lung cancer	3.24e-05	0.0003	CbGpPWpGaD
Methylphenidate—CYP2D6—Metabolism—ENO2—lung cancer	3.18e-05	0.000295	CbGpPWpGaD
Methylphenidate—CYP2D6—Metabolism—HPGDS—lung cancer	3.18e-05	0.000295	CbGpPWpGaD
Methylphenidate—CYP2D6—Metabolism—PPP2R1B—lung cancer	3.16e-05	0.000293	CbGpPWpGaD
Methylphenidate—CYP2D6—Metabolism—GSTT1—lung cancer	3.08e-05	0.000286	CbGpPWpGaD
Methylphenidate—CYP2D6—Metabolism—GCLC—lung cancer	3.05e-05	0.000282	CbGpPWpGaD
Methylphenidate—CYP2D6—Metabolism—CYP2A6—lung cancer	3.05e-05	0.000282	CbGpPWpGaD
Methylphenidate—CYP2D6—Metabolism—ENO1—lung cancer	2.89e-05	0.000268	CbGpPWpGaD
Methylphenidate—CYP2D6—Metabolism—CYP2E1—lung cancer	2.59e-05	0.00024	CbGpPWpGaD
Methylphenidate—CYP2D6—Metabolism—NQO1—lung cancer	2.56e-05	0.000237	CbGpPWpGaD
Methylphenidate—CYP2D6—Metabolism—STK11—lung cancer	2.31e-05	0.000214	CbGpPWpGaD
Methylphenidate—CYP2D6—Metabolism—GSTP1—lung cancer	2.14e-05	0.000198	CbGpPWpGaD
Methylphenidate—CYP2D6—Metabolism—CAT—lung cancer	2.08e-05	0.000193	CbGpPWpGaD
Methylphenidate—CYP2D6—Metabolism—ABCB1—lung cancer	2.02e-05	0.000187	CbGpPWpGaD
Methylphenidate—CYP2D6—Metabolism—TYMS—lung cancer	1.99e-05	0.000184	CbGpPWpGaD
Methylphenidate—CYP2D6—Metabolism—GSTM1—lung cancer	1.96e-05	0.000182	CbGpPWpGaD
Methylphenidate—CYP2D6—Metabolism—CYP1A1—lung cancer	1.86e-05	0.000173	CbGpPWpGaD
Methylphenidate—CYP2D6—Metabolism—ERCC2—lung cancer	1.85e-05	0.000171	CbGpPWpGaD
Methylphenidate—CYP2D6—Metabolism—APOA1—lung cancer	1.6e-05	0.000148	CbGpPWpGaD
Methylphenidate—CYP2D6—Metabolism—PIK3CG—lung cancer	1.46e-05	0.000135	CbGpPWpGaD
Methylphenidate—CYP2D6—Metabolism—POMC—lung cancer	1.39e-05	0.000129	CbGpPWpGaD
Methylphenidate—CYP2D6—Metabolism—CREBBP—lung cancer	1.35e-05	0.000125	CbGpPWpGaD
Methylphenidate—CYP2D6—Metabolism—PIK3CD—lung cancer	1.28e-05	0.000119	CbGpPWpGaD
Methylphenidate—CYP2D6—Metabolism—ALB—lung cancer	1.26e-05	0.000117	CbGpPWpGaD
Methylphenidate—CYP2D6—Metabolism—PIK3CB—lung cancer	1.12e-05	0.000104	CbGpPWpGaD
Methylphenidate—CYP2D6—Metabolism—PTGS2—lung cancer	1.11e-05	0.000103	CbGpPWpGaD
Methylphenidate—CYP2D6—Metabolism—PTEN—lung cancer	9.65e-06	8.95e-05	CbGpPWpGaD
Methylphenidate—CYP2D6—Metabolism—EP300—lung cancer	9.2e-06	8.53e-05	CbGpPWpGaD
Methylphenidate—CYP2D6—Metabolism—PIK3CA—lung cancer	6.81e-06	6.31e-05	CbGpPWpGaD
Methylphenidate—CYP2D6—Metabolism—AKT1—lung cancer	5.56e-06	5.16e-05	CbGpPWpGaD
